Phase 1 N=10 A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne
Acne Vulgaris
Primary: Number of Participants With Successful Engraftment of Probiotic Following a Single Application. — 2; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=41 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RO7062931 in Healthy Chinese Volunteers.
Healthy Participants
Primary: Percentage of Participants With Adverse Events and AEs of Special Interest — 66.7; 62.5; 62.5; 75.0 Percentage of Participants
Phase 1 N=36 A Study of the Safety, Engraftment, and Action of Multi-Dosed NB01 in Adults With Moderate Acne
Acne Vulgaris
Primary: Number of Participants With Changes in Local Skin Reactions — 19; 11; 2; 1 Participants
N/A N=105 Quartet Lead and Resynchronization Therapy Options III (QUARTO_III)
Heart Failure
Primary: Number of CRT Responders — 53 Participants — p=0.0435
Phase 3 N=351 Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Cerebral Palsy · Spasticity
Primary: MP: Change From Baseline in Ashworth Scale (AS) in UL Primary Clinical Target Pattern at Week 4 — -0.93; -1.15; -0.96; -1.02 Unit on a scale — p== 0.017
N/A N=10 Clinical Evaluation of Invigor Toric 1-Day Contact Lenses
Astigmatism
Primary: Visibility of Toric Mark — 100; 100; 0; 0 percentage of participants
Phase 4 N=44 Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis
Iron Overload
Primary: Number of Participants With Selected Gastrointestinal Disorders up to 24 Weeks — 0; 0; 0; 0 Participants
Phase 1 N=12 The Influence of ANS-6637 on Midazolam Pharmacokinetics in Healthy Volunteers
Opiod Use Disorder
Primary: Pharmacokinetics - Time to Maximum Concentration of Midazolam Alone — 0.58 hours
N/A N=22 Assessment of Two New Electronic Cigarettes in Cigarette Smokers
Electronic Cigarettes
Primary: Change in Plasma Nicotine — 7.62; 10.65; 18.31; 7.19 ng/ml
N/A N=45 Effect of TrueTear Corneal Surface Imaging
Cataract · Myopia
Primary: Surface Asymmetry Index (SAI) Assessed With Corneal Topography — 0.21 unitless
Phase 2 N=94 Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease
Crohn's Disease
Primary: Crohn's Disease Activity Index (CDAI) Response (Clinical Response or Remission) at Week 6 — 25.0; 43.3; 48.4 percentage of subjects
N/A N=118 Remotely-Delivered Benefits Counseling for Service Connection Applicants
Job Satisfaction · Unemployment
Primary: Hours Per Week of Paid Work — 2.8; 2.0; 4.8; 4.0 hours per week
Phase 3 N=34 Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
Neovascular Age Related Macular Degeneration
Primary: The Safety of Brolucizumab 6 mg Delivered in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration — 0; 0 Participants
N/A N=53 Evaluation of Long-term Buprenorphine Plasma Exposure
Opioid-use Disorder
Primary: Qualitative Urinary Drug Screen (UDS) for Buprenorphine in Parts A + B — 27; 19; 16; 15 Participants
Phase 2 N=11 St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene
HIV Infection · Alcohol Use · Pain
Primary: Medication Tolerability Measured Via a 0-100 Visual Analog Scale — 90.7; NA score on a scale